Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  selumetinib
Find trials that include:  Any drugs shown
Results 1-12 of 12 for your search:
Start Over
Selumetinib in Treating Young Patients with Recurrent or Refractory Low Grade Glioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: PBTC-029, NCI-2012-03173, CDR667932, PBTC-029B, NCT01089101
Selumetinib in Treating Younger Patients with Neurofibromatosis Type 1 or Plexiform Neurofibromas That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 18
Trial IDs: 8799, NCI-2013-01491, 748727, P11809, 11-C-0161, NCT01362803
Iodine I-131 with or without Selumetinib in Treating Patients with Recurrent or Metastatic Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RU241306I, NCI-2015-00277, 14-008494, NCT02393690
Selumetinib in Treating Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9840, NCI-2015-00456, 16-C-0043, NCT02407405
Selumetinib in Treating Patients with Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9990, NCI-2016-01087, NCT02839720
Selumetinib Sulfate in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer with KRAS G12R Mutations
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10050, NCI-2017-00118, NCT03040986
Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 12 months to 21 years
Trial IDs: APEC1621SC, NCI-2017-01251, NCT03155620
Pediatric MATCH: Selumetinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with Activating MAPK Pathway Mutations
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 12 months to 21 years
Trial IDs: APEC1621E, NCI-2017-01250, NCT03213691
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5160C00006, NCI-2014-02005, NCT02143466
Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients with stage IIIB-IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB00011462, NCI-2015-01018, 11,462, SOL-15008-L, NCT02503358
Selumetinib Sulfate in Treating Patients with Uveal Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAQ6999, NCI-2016-01205, NCT02768766
Start Over